emat

Buy Complete Report

Prix: €120 HT

Logo CreditCards Visa Logo CreditCards Mastercard

This report is accessible on EMAT, the reference database for private company acquisition multiples

 

 

► Subscribe to EMAT database

 

Sectors covered by our analysts

 

► Studies & indices published by Epsilon Research: Register to receive (free) publications updates

 

► Alert on reports published: Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

 

Transaction Multiples for the Valuation of Private Companies

Private Group led by Novalpina Capital / Laboratoire X.O

No EMAT : 102982
Announced Date : 10/11/2020
Type : LBO (Leverage Buy Out)
Deal Value : Yes
Acquirer : Private Group led by Novalpina Capital

Target : Laboratoire X.O
Country : Hauts-De-Seine
Sector of activity :
  • Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
  • Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Personal Products
Business Description :
Co-founded in 2015 by Karine Pinon and Gerard Leduc, Laboratoire X.O is a specialty pharmaceutical company that markets and sells a range of prescription and OTC drugs in France and internationally...

Transaction multiples available
EV/
Sales
EV/
Gross Profit
EV/
EBITDA
EV/
EBIT
Eq/
PBT
P/E Price
to Book
Specific
multiple(s)
Historic
Current
Rating : *
Multiple available
n.s.   Multiple calculated, but not significant

Source: Epsilon Research / EMAT

Comparable Transactions

  • Number of EMAT Reports / sub-sector « Pharmaceuticals » = 127
  • Number of EMAT Reports / sub-sector « Personal Products » = 127
Example of comparable transactions on EMAT (same sub-sector):
Date Acquirer Target Country Multiples See details
05/03/2019 Funding round led by Ouest Croissance, Unexo, Arkéa Capital Investment Nature et Stratégie Maine-Et-Loire * 102609
24/10/2016 Technature Laboratoires Science et Mer Finistère * 102591

Source: Epsilon Research / EMAT

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

EMAT Report

► Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

 

► Example of EMAT Report